<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>personalized cancer immunotherapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/personalized-cancer-immunotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 26 Jan 2026 02:46:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>personalized cancer immunotherapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Enhancing CAR-T Cells: Targeting Tumor Characteristics</title>
		<link>https://bioengineer.org/enhancing-car-t-cells-targeting-tumor-characteristics/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 26 Jan 2026 02:45:49 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[and overcoming limitations]]></category>
		<category><![CDATA[and personalized approaches]]></category>
		<category><![CDATA[Based on the content focusing on next-gen CAR-T cells targeting tumor-specific features]]></category>
		<category><![CDATA[Based on the content focusing on next-generation CAR-T cell design]]></category>
		<category><![CDATA[Combination cancer therapies]]></category>
		<category><![CDATA[combination immunotherapy]]></category>
		<category><![CDATA[CRISPR gene-editing]]></category>
		<category><![CDATA[here are 5 appropriate tags: **Next-generation CAR-T]]></category>
		<category><![CDATA[here are 5 suitable tags: **Next-generation CAR-T cells]]></category>
		<category><![CDATA[microenvironment adaptation]]></category>
		<category><![CDATA[personalized cancer immunotherapy]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tumor microenvironment targeting]]></category>
		<category><![CDATA[tumor targeting]]></category>
		<guid isPermaLink="false">https://bioengineer.org/enhancing-car-t-cells-targeting-tumor-characteristics/</guid>

					<description><![CDATA[In a groundbreaking advancement in cancer immunotherapy, researchers have unveiled the next-generation design of CAR-T cells that strategically leverage unique tumor features to enhance therapeutic efficacy. This innovative approach promises to significantly improve patient outcomes in the ongoing battle against resilient malignancies. By capitalizing on tumor heterogeneity and microenvironmental cues, this study paves the way [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320878</post-id>	</item>
		<item>
		<title>Personalizing Cancer Vaccines for Enhanced Treatment</title>
		<link>https://bioengineer.org/personalizing-cancer-vaccines-for-enhanced-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Oct 2025 14:23:59 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AI-driven cancer vaccine design]]></category>
		<category><![CDATA[cutaneous squamous cell carcinoma research]]></category>
		<category><![CDATA[personalized cancer immunotherapy]]></category>
		<category><![CDATA[structural neoantigen analysis]]></category>
		<category><![CDATA[tumor immune recognition mechanisms]]></category>
		<guid isPermaLink="false">https://bioengineer.org/personalizing-cancer-vaccines-for-enhanced-treatment/</guid>

					<description><![CDATA[University of Arizona Researchers Harness AI to Unlock the Structural Secrets of Tumor-Rejecting Neoantigens in Skin Cancer In a groundbreaking advancement in cancer immunotherapy, scientists at the University of Arizona have unveiled a novel approach to identifying and characterizing neoantigens—mutated tumor proteins that potentially serve as critical targets for personalized cancer vaccines. Their recent study, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287127</post-id>	</item>
		<item>
		<title>New Immune Cell Model Predicts Ovarian Cancer Outcomes</title>
		<link>https://bioengineer.org/new-immune-cell-model-predicts-ovarian-cancer-outcomes/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 08 Sep 2025 03:23:50 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Immune cell-based model]]></category>
		<category><![CDATA[Multiplex immunofluorescence]]></category>
		<category><![CDATA[Ovarian cancer prognosis]]></category>
		<category><![CDATA[personalized cancer immunotherapy]]></category>
		<category><![CDATA[tumor microenvironment dynamics]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-immune-cell-model-predicts-ovarian-cancer-outcomes/</guid>

					<description><![CDATA[In a significant advancement for oncology, researchers Wu et al. have initiated a groundbreaking approach to ovarian cancer prognosis through the development of a novel immune cell-based model, meticulously utilizing multiplex immunofluorescence techniques. This innovative model has the potential to transform how clinicians assess disease outcomes, emphasizing the critical role that the immune system plays [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">267422</post-id>	</item>
		<item>
		<title>Cell-Based Vaccine Enhances Liver Cancer Therapy, Slowing Disease Progression in Patients</title>
		<link>https://bioengineer.org/cell-based-vaccine-enhances-liver-cancer-therapy-slowing-disease-progression-in-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 26 Aug 2025 16:37:00 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[chemoembolization combination therapy]]></category>
		<category><![CDATA[dendritic cell vaccine clinical trial]]></category>
		<category><![CDATA[hepatocellular carcinoma immunotherapy]]></category>
		<category><![CDATA[liver cancer progression delay]]></category>
		<category><![CDATA[personalized cancer immunotherapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cell-based-vaccine-enhances-liver-cancer-therapy-slowing-disease-progression-in-patients/</guid>

					<description><![CDATA[In a groundbreaking advancement for liver cancer treatment, researchers from the University of Birmingham have demonstrated that a novel dendritic cell (DC) vaccine, when combined with established chemoembolization therapy, significantly extends the time patients remain free from tumor progression. This pioneering study, funded by the National Institute for Health and Care Research (NIHR) and published [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">258120</post-id>	</item>
		<item>
		<title>Breakthrough Cell Therapy Demonstrates Promising Outcomes in Treating Advanced Tumors</title>
		<link>https://bioengineer.org/breakthrough-cell-therapy-demonstrates-promising-outcomes-in-treating-advanced-tumors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 25 Apr 2025 16:08:20 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[advanced solid tumor treatment]]></category>
		<category><![CDATA[durable cancer remission]]></category>
		<category><![CDATA[personalized cancer immunotherapy]]></category>
		<category><![CDATA[PRAME-targeted immunotherapy]]></category>
		<category><![CDATA[TCR-engineered T cell therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/breakthrough-cell-therapy-demonstrates-promising-outcomes-in-treating-advanced-tumors/</guid>

					<description><![CDATA[A groundbreaking development in cancer immunotherapy has emerged from Dresden University Hospital, where researchers have announced promising results from a phase 1 clinical trial utilizing T cell receptor (TCR)-engineered T cells. This innovative approach involves genetically modifying a patient’s own immune cells to specifically recognize and attack tumor cells while sparing healthy tissues. The trial’s [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">242240</post-id>	</item>
	</channel>
</rss>
